Restless Legs Syndrome: Challenges to Treatment.
Sleep Med Clin
; 16(2): 269-277, 2021 Jun.
Article
em En
| MEDLINE
| ID: mdl-33985652
For a long time, dopaminergic treatment (DT) was the medication for restless legs syndrome. Although DT is effective and safe over the short-term, complications develop over longer periods, including augmentation, tolerance, and impulse control disorders. Nowadays, it is recommended that first-line treatment should be alpha-2 ligands, which are more effective in the absence of previous DT. As a second-line treatment, opioids, such as oxycodone extended-release with naloxone, are approved in Europe. Brain iron should be monitored before and during treatment and corrected if necessary. Two new promising non-DTs are being developed: perampanel and dipyridamole. More research is needed.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Síndrome das Pernas Inquietas
Tipo de estudo:
Clinical_trials
Limite:
Humans
Idioma:
En
Revista:
Sleep Med Clin
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Chile
País de publicação:
Estados Unidos